Key Takeaways Danaher's Q3 adjusted EPS rose 11.6% to $2.11, beating estimates by 9.9%.Diagnostics sales jumped 17%, driven by acquisitions, while core sales excluding respiratory testing rose 7%.Danaher raised 2026 adjusted EPS guidance to $8.57-$8.62, targeting 2.5% core revenue growth.Danaher Corporation (DHR) reported third-quarter 2026 adjusted earnings of $2.11 per share, beating the Zacks Consensus Estimate of $1.92 by 9.9%. The bottom line increased 11.6% year over year from $1.89 per share. Stronge ...